Better acute graft-
            <i>versus</i>
            -host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Gooptu, Mahasweta; Koreth, John

doi:10.3324/haematol.2017.165266

Cited by 15 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to a previous report, the severity of aGVHD decreases over time. 37 However, transplantation procedures, including empiric antibiotic strategy, have not changed from 2013 to 2017. Furthermore, the cumulative incidence of aGVHD in early 2017 was comparable with that in the historical control group, not the prebiotics group (supplemental Figure 1).…”

Section: Discussionmentioning

confidence: 99%

Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation

et al. 2020

View full text Add to dashboard Cite

Acute graft-versus-host disease (aGVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Therefore, management of aGVHD is important for successful transplantation. Mucosal damage and alteration of the gut microbiota after allo-HSCT are key factors in the development of aGVHD. We conducted a prospective study to evaluate the ability of prebiotics, which can alleviate mucosal damage and manipulate the gut microbiota, to mitigate posttransplantation complications, including aGVHD. Resistant starch (RS) and a commercially available prebiotics mixture, GFO, were administered to allo-HSCT recipients from pretransplantation conditioning to day 28 after allo-HSCT. Prebiotic intake mitigated mucosal injury and reduced the incidence of all aGVHD grades combined and of aGVHD grades 2 to 4. The cumulative incidence of skin aGVHD was markedly decreased by prebiotics intake. Furthermore, the gut microbial diversity was well maintained and butyrate-producing bacterial population were preserved by prebiotics intake. In addition, the posttransplantation fecal butyrate concentration was maintained or increased more frequently in the prebiotics group. These observations indicate that prebiotic intake may be an effective strategy for preventing aGVHD in allo-HSCT, thereby improving treatment outcomes and the clinical utility of stem cell transplantation approaches. This study was registered on the University Hospital Medical Information Network (UMIN) clinical trials registry (https://www.umin.ac.jp/ctr/index.htm) as #UMIN000027563.

show abstract

Section: Discussionmentioning

confidence: 99%

Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…aGvHD -acute graft-versus-host disease; cGvHD -chronic graft-versus-host disease; M -male; F -female; EBMT -European Society for Blood and Marrow Transplantation increases with increasing severity of GvHD [3,7]. Our study is an example of the impact of aGvHD evaluation on the outcome of allogeneic transplants and, on the other hand, the lack of effective treatment when the disease is higher than grade III.…”

Section: Discussionmentioning

confidence: 75%

“…Acute GvHD (aGvHD) continues to be an important complication following allo-HCT in the modern era [3]. In the early period (first 100 days) after transplantation, aGvHD develops in 25-75% of patients, and the skin, liver, and gastrointestinal tract are targeted.…”

Section: Introductionmentioning

confidence: 99%

Graft-versus-host disease in patients treated with allogenic hematopoetic cell transplantation: experience from North Macedonia

Mickovski¹,

Ilievska

Georgievski

et al. 2021

Acta Haematol Pol.

View full text Add to dashboard Cite

Introduction: Graft-versus-host disease (GvHD) is the major complication arising after allogeneic hematopoietic cell transplantation (allo-HCT). It can present as acute and/or chronic GvHD. The purpose of this study was to describe the incidence of acute and chronic GvHD in patients treated with allo-HCT.Materials and methods: This study was designed as a retrospective study, which included 65 patients treated with allogeneic transplantation from a human leukocyte antigen identical donor at the University Clinic of Hematology in Skopje, North Macedonia.Results: Acute GvHD (aGvHD) was observed in 28 patients, with the most common localization on the skin (75%). Post-transplant phase had a significant effect on the frequency of skin aGvHD (p =0.038). Also a statistically significant difference was confirmed between patients with and without acute skin GvHD in terms of conditioning regimen (p =0.034). Chronic GvHD (cGvHD) was diagnosed in 10 patients, mostly progressing from previously acute GvHD (9.23%). Post-transplant phase had also a significant effect on the frequency of skin cGvHD (p =0.018). Patients with a higher European Society for Blood and Marrow Transplantation risk score had significantly more frequent skin cGvHD than did the others.Conclusions: Acute and chronic GvHD are leading causes of morbidity and mortality of patients after allo-HCT. GvHD remains a major risk for patients with allo-HCT, regardless of diagnosis or type of transplantation.

show abstract

“…The cells to be transplanted are first collected through apheresis or cell cultivation, with apheresis being the most common procedure in Mexico. After that, a conditioning regimen is given to destroy the recipient's bone marrow, to finally give the previously collected cells to reestablish the hematopoietic system 3 .…”

Section: Stem Cell Transplant and Graft-versus-host Diseasementioning

confidence: 99%

Role of the human chorionic gonadotropin in treating graft-versus-host disease: a brief review

Martínez-Hernández,

Gómez-Peña,

Gómez-Almaguer

2023

RMU

View full text Add to dashboard Cite

Human chorionic gonadotropin is one of the primary hormones produced during pregnancy, enabling its maintenance and viability. Among its various effects on the body, it has been of particular interest in recent years its role in the immunosuppression and immunoregulation that has been noted to occur during pregnancy. Since besides preventing the body from attacking the embryo, it has been noted that there is a reduction in the activity of diseases with an autoimmune component. Hence, it has been theorized that it can be used as part of the treatment of graft-versus-host disease since it is a relatively safe molecule. There have been various studies, such as those made by Elmaagacli et al. and Holtan et al., in which the results have been promising. Still, stronger evidence obtained from randomized studies must be obtained before including it in the standard of care of international guidelines.

show abstract

Better acute graft- versus -host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Cited by 15 publications

References 13 publications

Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation

Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation

Graft-versus-host disease in patients treated with allogenic hematopoetic cell transplantation: experience from North Macedonia

Role of the human chorionic gonadotropin in treating graft-versus-host disease: a brief review

Contact Info

Product

Resources

About